RVO is caused by thrombotic occlusion of the central retinal vein or one of its branches (1) (2) (3) (4) (5) (6) 9, 10) . RVO can be severely debilitating, commonly causing reduced visual acuity, neurovascular glaucoma, and, occasionally, blindness (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) .
We previously assessed thrombophilia and hypofibrinolysis as possible causes of RVO (1) . In 14 cases with RVO compared to controls (1), there was an increased prevalence of the thrombophilic G1691A factor V Leiden mutation (18% vs 3%, p = .02), as well as three hypofibrinolytic traits: an increase in the 4G mutation of the PAI-1 gene (88% vs 64%, p = .03), high levels of PAI-Fx (> 21.1 U/mL, 38% vs 2%, p = .001), and high (≥ 35 mg/dL) levels of Lp (a) (50% vs 13%, p = .003). The factor V Leiden mutation has been identified as a risk factor for RVO in many (1, 2, 8) , but not all studies (5) .
Further confirmation of causal relationships between hypofibrinolysis-thrombophilia and RVO, accompanied by better understanding of the molecular genetic causes of thrombosis, should facilitate the surveillance, prevention, and treatment of RVO. Incorvaia and colleagues prevented recurrent retinal vein occlusion by anticoagulation in a patient who was heterozygous for the factor V Leiden mutation (8) . The association of RVO with hypofibrinolysis and thrombophilia also has broad clinical implications because these coagulation disorders can cause preventable/reversible deep vein thrombosis (11) , pulmonary embolism (11) , NAION (12) , ischemic cerebral vascular accidents (13) , myocardial infarction (13) , osteonecrosis (14) , and major complications of pregnancy (15) .
In this study, we prospectively assessed whether thrombophilia and hypofibrinolysis, amplified by thrombophilic hormone replacement therapy (HRT), were associated with RVO.
METHODS

Study Protocol, Cases
Consent was obtained after the nature of the procedures had been fully explained. The procedures followed were in accordance with the ethical standards of the Institutional Review Board of the Jewish Hospital, Cincinnati, Ohio, which approved the research protocol.
We prospectively studied 44 cases, 42 with central and two with branch RVO, in the consecutive order of their referral by two communitybased ophthalmologists. Three or more months after their RVO event, PCR-cDNA and serologic coagulation assays were done in an outpatient clinical research center (Tables 1, 2; Fig. 1 ). No patients had taken warfarin or heparin within 3 months of blood sampling. To assess associations of coagulation disorders and RVO at or under the age of 55 years, we analyzed 23 cases age 55 or younger as a subset of the full cohort of 44 cases (Figs. 1, 2 ; Tables 1, 2 ).
Blood specimens for lipid profiles and coagulation measures (Tables 1, 2) were obtained between 8 and 10 AM after an overnight fast from seated cases and controls as previously described (1, 12) .
Retinal vein occlusion was diagnosed by the referring ophthalmologist based on the results of characteristic fundus features (1) (2) (3) (4) (5) , including disc swelling, venous dilation or tortuosity, retinal hemorrhages, and cotton-wool spots; and by fluorescin angiography demonstrating extensive areas of capillary closure, venous filling defects, and increased venous transit time.
At the cases' initial visit in our outpatient clinical research center, 3 or more months after their RVO, a detailed history and physical examination was carried out with a focus on cardiovascular events, hypertension, diabetes, pulmonary embolus, deep venous thrombosis, reproductive history, hormone replacement therapy (HRT), and therapy for hypertension, diabetes, and hyperlipidemia.
Controls
For comparison with the cases' DNA polymorphisms, 83 healthy adult controls were used, 40 hospital personnel and 43 subjects before orthopedic surgery (Fig. 1 ). The controls were not pregnant, and not taking medications known to affect coagulation measures. For comparison with cases' serologic coagulation measures, 40 healthy adult controls were used (12) . Dilute Russel's Viper venom time (DRVVT) and activated partial thromboplastin time (APTT) were available in 32 of the 40 controls.
For comparison with cases age 55 or younger (n=23), 44 controls age 55 or younger were used for the PCR assays, and 40 age 55 or younger for serologic measures (Fig. 2) .
Polymerase Chain Reaction-cDNA Assays
Polymerase chain reaction (PCR)-cDNA coagulation measures ( Table 2) were performed in cases with RVO and in healthy controls using previously published methods by laboratory staff blinded to the subjects' status (case, control, severity of cases) (1, 12, (14) (15) (16) (17) (18) (19) (20) (21) . The PCR analyses of four thrombophilic gene mutations (G1691A factor V Leiden, C677T MTHFR, G20210A prothrombin, platelet glycoprotein IIb/IIIa PL A1/A2 polymorphism) and the hypofibrinolytic 4G/5G mutation of the PAI-1 gene promoter were performed at the Molecular Diagnostics Laboratory in Cincinnati, using previously published methods, as summarized in the Appendix (1, 12, (14) (15) (16) (17) (18) (19) (20) (21) .
Serologic Measures of Thrombophilia
Measures of thrombophilia included anticardiolipin antibodies (IgG and IgM), antigenic protein C, total and free protein S, antithrombin III, resistance to activated protein C (RAPC), activated partial thromboplastin time (APTT), dilute Russel's Viper Venom time (DRVVT), factors VIII and XI, and homocysteine (Alliance Hospital Laboratories, Cincinnati, Ohio) ( Table 2) . Established, previously published methods were used, as summarized in the Appendix (1, 12, 14, 16, 17) . Differences between RVO cases and controls for resistance to activated protein C (RAPC), the 4G allele of the plasminogen activator inhibitor (PAI-1) gene, plasminogen activator inhibitor activity (PAI-Fx) after covariance adjustment for for age, gender, and race, and factor VIII.
FIG. 2.
Differences between RVO cases age 55 years or younger (n = 23) and controls age 55 or younger (n for PCR = 44, n for serologic measures =40) for resistance to activated protein C (RAPC), heterozygosity for the G1691A factor V Leiden mutation, the 4G allele of the plasminogen activator inhibitor (PAI-1) gene, plasminogen activator inhibitor activity (PAI-Fx) after covariance adjustment for age, gender, and race, and factor VIII.
APPENDIX: HEMOSTASIS MEASURES
Blood samples for DNA analysis were collected in EDTA solution and were processed within 4 hours. Genomic DNA for the PCR assays was obtained by a simple salting out procedure (ethanol extraction).
After a 12-hour fast, and with the patient seated for 5-10 minutes in the early morning, blood was drawn from the antecubital vein to minimize circadian influence on fibrinolytic activity (17) . After discarding the first 3 mL, blood was collected in 5-mL 3.2% sodium citrate vacutainer tubes. Platelet-poor plasma was obtained by centrifugation at 4°C for 15 minutes at 2600g and was snap-frozen and stored at -70°C until processed. 
Hemostasis Assays, Plasma
Serologic Measures of Hypofibrinolysis
The major hypofibrinolytic factors, Lp(a) and PAI-Fx, were measured using established, previously published methods (Alliance Hospital Laboratories), as summarized in the Appendix (1, 12, 14, 16, 17) .
Risk Factors for Cardiovascular Disease
After an overnight fast, blood was obtained for measurement of cholesterol, triglyceride, highdensity lipoprotein (HDL) cholesterol, and lowdensity lipoprotein (LDL) cholesterol by established, previously published methods (Alliance V Leiden mutation: G1691A Factor V mutation in the Factor V gene. Resistance to activated protein C caused by a CGA→CAA substitution at position 1691 of the Factor V gene (Leiden mutation), Fluorescence monitoring using hybridization probes (21) PAI-1 gene polymorphism: Single base guanosine insertion/deletion, commonly called 4G/5G in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene.The PAI-1 4G/5G mutation was determined with 5'-GAG AGT CTG GAC ACG TCC GG-3' as the mutagenic forward primer and 5'-AAC AGC CAC AGG GCA TGC A-3' as the reverse primer. The thermal cycling conditions were initial denaturation 95º 5', and then 33 cycles of 95º 5', 58º 2', and 72º 1.15'. The PCR product was digested with BspE I enzyme (NEB) and then the bands resolved on an 8% polyacrylamide gel (14, 15) .
Hospital Laboratories, Cincinnati, Ohio; (24) , triglycerides at 150 mg/dL or higher were identified as high, and HDL cholesterol less than 50 mg/dL in women and less than 40 mg/dL in men as low (Table 1) . Hyperlipidemia was further diagnosed by referring physicians' use of lipid-lowering drugs. Blood pressure was measured in seated subjects after a 5-minute or longer resting period (Table 1) ; systolic blood pressure 130 mm Hg or greater or diastolic blood pressure 85 mm Hg or greater were identified as high as per guidelines for diagnosis of the metabolic syndrome (24) . Hypertension was further identified by the referring physicians' use of antihypertensive agents.
Type 2 diabetes was diagnosed by the referring physicians' use of insulin-sensitizing drugs and/or insulin secretogogues or by fasting plasma glucose 126 mg/dL or greater without drug therapy for diabetes (24) . Fasting blood glucose 110 mg/dL or higher was identified as high (Table 1) (24) .
Statistical Methods
Proportions of RVO cases and controls having abnormalities in coagulation measures were compared using chi square analysis or the Fisher exact test when cell size was less than 5 ( Fig. 1 ) (25) . Comparison of median values in cases versus controls was done by Wilcoxon non-parametric tests (25) . Spearman correlations (25) were used to assess correlations of age to serologic measures of coagulation in cases and in controls (25) . Serologic measures were covariance adjusted for age, race, and gender to allow further comparison of cases versus controls (25) .
Stepwise logistic regressions were done with RVO cases and controls (n = 83) as a binary dependent variable and explanatory variables including age, gender, race, the G1691A factor V Leiden mutation, the G20210A mutation of the prothrombin gene, the C677T mutation of the MTHFR gene, the 4G5G PAI-1 gene mutation, and the PL A1/A2 polymorphism of the platelet glycoprotein IIb/IIIa gene (25) . A separate step-wise logistic regression model was run for 23 cases age 55 or younger and 44 controls age 55 or younger.
RESULTS
Coagulation Measures (Gender, Age, Race Effects)
The 44 cases with RVO did not differ (p > 0.1) from the 83 controls used for PCR analyses by race, 5:44 non-white (11%) versus 7/83 (8%); by gender, 26:44 women (59%) versus 47/83 (57%); or by age, 57 ± 12 years versus 53 ± 18. Thus, case-control differences in the PCR measures could not be attributed to casecontrol differences in race, gender, or age.
The 44 cases with RVO did not differ from the 40 controls used for serologic measures for race, five non-whites (11%) versus four (10%), p = 0.84; or for gender, 26 women (59%) versus 23 (58%), p = 0.88; but did differ by age (57 ± 12 years versus 37 ± 7), p less than .0001. Similarly, the 23 cases age 55 or younger did not differ from the 40 controls age 55 or younger by gender or race, but were older, 48 ± 7 versus 37 ± 7, p less than .0001.
In the RVO cases, age did not correlate (p > 0.09) with any of the following serologic measures (RAPC, homocysteine, proteins C, S, free S, antithrombin III, ACLA IgG, ACLA IgM, PAI-Fx, Lp (a), factor VIII, factor XI, DRVVT, APTT). Age correlated only with free protein S in the 40 controls (r = .42, p = .007). Hence, any differences in coagulation measures between cases and controls, except for free protein S, could not be attributed to race, gender or age. Table 2 and Fig. 1 summarize coagulation measures in the full cohort of 44 RVO cases with comparisons against 83 healthy controls for the cDNA-PCR assays and to 40 healthy normal controls for the serologic assays. Fig. 2 displays significant case-control differences in the 23 cases age 55 years or younger versus controls 55 years or younger (44 for PCR, 40 for serologic measures).
Coagulation Disorders in RVO Cases
As displayed in Fig. 2 , cases age 55 years or younger differed from 55-year-old or younger controls for three thrombophilic traits: resistance to activated protein C (RAPC); high factor VIII; and, marginally for the G1691A factor V Leiden mutation. Thrombophilic RAPC was present in 3 of 18 (17%) cases versus 0 of 40 (0%) controls, Fisher's p [p f ] = .026. Thrombophilic high factor VIII (>150%) was present in 3 of 18 (17%) cases vs 0 of 40 (0 %) controls, p f = .026, Fig. 2 . Thrombophilic heterozygosity for the G1691A factor V Leiden mutation was present in 3 of 23 (13%) cases versus 1 of 44 (2%) controls, p f = .11. With alpha = 0.05, our sample size for the factor V Leiden case-control comparison had 40% power and a 60% likelihood of a type II error (failure to declare the case-control difference in the V Leiden mutation significant, when true differences existed). Cases also differed from controls for the hypofibrinolytic 4G polymorphism of the PAI-1 gene, and for its gene product, plasminogen activator inhibitor activity (PAI-Fx). The 4G allele frequency of the PAI-1 gene was 74% in cases vs 39% in controls (p = .0001) ( Fig. 2 ). PAI-Fx was higher in cases than controls (age-race-gender adjusted mean 12.7 U/mL versus 6.7, p = .016) ( Fig. 2) . By stepwise logistic regression, the PAI-1 gene 4G allele was associated with RVO, odds ratio 5.54, 95% CI 1.86-16.5, p = .002.
In the full cohort of 44 cases, RAPC was present in 6 of 32 (19%) cases versus 0 of 40 (0%) controls, Fisher's p [p f ] = .006 (Fig. 1) . The 4G allele frequency of the PAI-1 gene, associated with hypofibrinolysis, was 56 of 88 (64%) in cases versus 79 of 166 (48%) in controls, chi square = 5.95, p = .015. By stepwise logistic regression, the PAI-1 gene 4G allele was associated with RVO, odds ratio 1.94, 95% CI 1.12-3.34, p = .018. After covariance adjusting for age, gender, and race, cases had higher PAI-Fx, (12.2 versus 6.3 U/mL, p = .013). Thrombophilic high factor VIII (>150%) was present in 3 of 30 (10%) cases versus 0 of 40 (0%) controls, p = .041, p f = .07 ( Fig. 1) .
Of the 26 women, nine (35%) took HRT (Table 1) . Of the nine women on HRT, four (nos. 3, 4, 15, 30) (Table 2 ) had hypofibrinolytic 4G4G homozygosity of the PAI-1 gene, two (nos. 16, 24) had thrombophilic high anticardiolipin antibody (IgG), one was heterozygous for the thrombophilic G1691A factor V Leiden mutation (no. 30), and two were heterozygous for the thrombophilic PL A1/A2 Iib/IIIa platelet glycoprotein mutation (nos. 16, 35) . One of the nine women on HRT had high PAI-Fx (no. 39, Table 2 ). Only one of the nine women on HRT had no coagulation disorder (no. 41, Table 2 ).
Cardiovascular Risk Factors and Events
Of the 44 cases, 10 (23%) smoked; 25 (57%) had been treated for high triglycerides (16 of whom [64%] were receiving lipid-lowering drugs). One of the 44 cases (2.3%) (no. 22, Table 1 ) had type 2 diabetes. Of the 42 cases with fasting blood glucose measures, two (5%) had values 110 mg/dL or greater (24) ( Table 1) .
At the time of referral, many cases met the criteria for the metabolic syndrome (24) ( Table 1) . Of the 44 cases, 10 of 18 men (56%) had HDL cholesterol less than 40 mg/dL (24) , seven of 26 women (27%) had HDL cholesterol less than 50 mg/dL (24) , and 20 of 44 cases (45%) had triglycerides 150 mg/dL or greater (24) ( Table  1) . Systolic blood pressure was 130 mmHg or greater (24) in 27 cases (66%), and diastolic blood pressure was 85 mm Hg or greater (24) in nine (22%). Of the 44 cases, 20 (45%) had total cholesterol 200 mg/dL or greater (22) , and 17 (39%) had LDL cholesterol 130 mg/dL or greater (22) . Hypertension had been diagnosed in 22 of the 44 cases (50%), and 20 of these 22 (91%) were receiving antihypertensive medications. Body mass index (BMI) was greater than or equal to the Lipid Research Clinics (LRC) agegender-specific 90th percentile (23) in 14 of the 44 cases (32%), p < .0001 (Table 1) .
Of the 44 cases, nine (20%) had previously sustained transient ischemic attacks, 10 (23%) had ischemic strokes, eight (18%) had angina, and four (9%) had previous myocardial infarctions. The 26 women had 70 pregnancies, with 48 live births, and 20 spontaneous miscarriages (29%).
DISCUSSION
In this report, cases with RVO were more likely than normal controls to have thrombophilic RAPC, and thrombophilic high factor VIII. In cases 55 years old or younger, G1691 A heterozygosity for the factor V Leiden mutation was marginally more common than in 55-year-old or younger controls (13% versus 2%, p f = 0.11), consistent with the case-control differences in RAPC. For case-control comparisons of the V Leiden mutation at age 55 years or younger, at alpha = 0.05, our study had power of only 40%, with a 60% chance of a type II error, declaring the case-control V Leiden difference non-significant, when a true difference existed.
Cases were more likely than controls to have the hypofibrinolytic 4G mutant allele of the PAI-1 gene and higher levels of its hypofibrinolytic gene product, PAI-Fx. In both the full cohort and in cases age 55 or younger, the PAI-1 gene 4G allele was independently associated with RVO cases (odds ratio = 1.94, 95% CI 1.12-3.34, p = .018), (odds ratio 5.54, 95% CI 1.86-16.5, p = .002). The increased prevalence of the hypofibrinolytic PAI-1 4G allele and high PAI-Fx was similar to our previous study of 14 cases with RVO (1).
This study's finding of an increased prevalence of thrombophilic RAPC is congruent with the findings of Larsson and colleagues in 37 cases younger than age 50 with central RVO (3). Marucci and colleagues reported that resistance to activated protein C was an independent risk factor for central RVO in 53 cases (26) . Lerche and associates concluded that resistance to activated protein C was one of the most common causes for RVO, studying 66 cases (27) . Kuhli and coworkers evaluated resistance to activated protein C in 142 RVO cases and found APC resistance in 17% of cases age 45 or younger, versus 4.8% in young controls, and 5.3% in cases older than age 45 (28) . Kuhli and colleagues suggested screening for resistance to activated protein C in RVO cases age 45 or younger (28) . de Visser and associates reported that reduced sensitivity to activated protein C, not caused by the factor V Leiden mutation, is, itself, a risk factor for venous thrombosis (29) .
Our finding of high levels of thrombophilic factor VIII in cases versus controls is, apparently, a new association of thrombophilia with RVO. Boyd and colleagues compared 63 cases with CRVO versus 63 age-matched controls and did not find higher factor VIII levels in cases than controls (30) .
Overall, in this study, case-control differences in coagulation disorders were more pronounced in cases 55 years or younger, congruent with previous reports (3, 28) .
The 26 women with RVO had 70 pregnancies, 48 live births, and 20 spontaneous miscarriages (29%), 1.8 times the 15.7% reported from the National Survey of Family Growth (31), a population-based survey of US women ages 15 to 44 years. We speculate that this high level of spontaneous miscarriage reflects superposition of the physiologic thrombophilic hyperestrogenemia of pregnancy on an increased prevalence of heritable thrombophilia and hypofibrinolysis, leading to thrombotic placental insufficiency (15, 18) .
Of the 26 women, nine (35%) took HRT; eight of these nine women had a thrombophilic or hypofibrinolytic coagulation disorder. When the thrombophilia associated with HRT (12) (13) (14) (32) (33) (34) (35) is superimposed on heritable thrombophilia and hypofibrinolysis, the risk for arterial thrombosis is augmented in NAION (12) , and venous thrombosis in retinal vein occlusion (1) . Recognition that an estrogen-heritable coagulation disorder interaction (1, (12) (13) (14) (15) 18, (32) (33) (34) (35) may play an important role in RVO should facilitate stopping exogenous estrogens as a therapeutic intervention to limit further thrombosis in RVO.
Documentation of heritable coagulation disorders may, speculatively, be important for prevention of occlusion in the contralateral eye following its occurrence in the first eye, which may occur over a 5-year period in 11.9% of RVO (36) .
Coronary heart disease risk factors are recognized contributors to RVO (9, 10, 37) as in our study, where hypertriglyceridemia, obesity, and hypertension were very common. Of the 44 RVO cases, using the cutpoints for the metabolic syndrome (24), 20 (45%) had high triglycerides (≥ 150 mg/dL). At the time of referral, high triglycerides had been diagnosed by family physicians in 25 cases (57%); 16 of these 25 hyperlipidemic cases (64%) were receiving lipid-lowering drugs. Systolic blood pressure was high (24) (≥ 130 mm Hg) in 66% cases, and diastolic blood pressure was high (≥ 85 mm Hg) in 22%. At the time of referral, hypertension had been diagnosed in 50% of cases. BMI was skewed into the population upper decile, with 32% of cases having BMI greater than or equal to the Lipid Research Clinics 90th percentile (23) p < .0001. Not surprising in the face of the large percent of cases with coronary heart disease risk factors (24) , of the 44 RVO cases, 20% had sustained transient ischemic attacks, 23% had ischemic strokes, 18% angina, and 9% previous myocardial infarctions.
We suggest that cases with RVO, particularly those age 55 or younger, those with concurrent "environmental" acquired thrombophilia (HRT, oral contraceptives, pregnancy), and those with a personal or family history of thrombosis (37) , have diagnostic evaluation for coagulation disorders. In cases with RVO, beyond treatable cardiovascular risk factors, common in our cases and in other series (9,10,33), we suggest measuring the PAI-1 genotype, PAI-Fx, factor VIII, resistance to activated protein C, and the G1691A V Leiden mutation. The presence of multiple coagulation risk factors promotes development of RVO (33) . Particularly in the presence of multiple coagulation risk factors (37, 38) , we believe that potentially reversible thrombosis leads to acute decompensation of the blood supply to the optic disc (8) . In RVO, as well as in retinal artery thrmbosis (39) , definition of coagulation etiologies is important because, as concluded by Bick and colleagues (38) : ". . . it allows for definition of appropriate acute antithrombotic therapy and subsequent thromboprophylaxis to prevent additional visual loss and also allows identification of those patients with thrombophilias so other thrombotic events can be avoided and appropriate family members assessed when clinically warranted."
